Aldo is one of only a few UK patients who took part in an Alzheimer drug trial, now approved for use in the US.

Source

There has been controversy around aducanumab, which targets the cause rather than the symptoms.

Source

Matt Hancock says 21 June is a "not before" date for ending England's remaining restrictions.

Source